Prognosis of critically ill immunocompromised patients with virus-detected acute respiratory failure.
Immunocompromised
Influenza
Mechanical ventilation
Pneumonia
Respiratory virus
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
13 Oct 2023
13 Oct 2023
Historique:
received:
07
07
2023
accepted:
26
09
2023
medline:
14
10
2023
pubmed:
14
10
2023
entrez:
13
10
2023
Statut:
epublish
Résumé
Acute respiratory failure (ARF) is the leading cause of ICU admission. Viruses are increasingly recognized as a cause of pneumonia in immunocompromised patients, but epidemiologic data are scarce. We used the Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie's database (2003-2017, 72 intensive care units) to describe the spectrum of critically ill immunocompromised patients with virus-detected ARF and to report their outcomes. Then, patients with virus-detected ARF were matched based on clinical characteristics and severity (1:3 ratio) with patients with ARF from other origins. Of the 4038 immunocompromised patients in the whole cohort, 370 (9.2%) had a diagnosis of virus-detected ARF and were included in the study. Influenza was the most common virus (59%), followed by respiratory syncytial virus (14%), with significant seasonal variation. An associated bacterial infection was identified in 79 patients (21%) and an invasive pulmonary aspergillosis in 23 patients (6%). The crude in-hospital mortality rate was 37.8%. Factors associated with mortality were: neutropenia (OR = 1.74, 95% confidence interval, CI [1.05-2.89]), poor performance status (OR = 1.84, CI [1.12-3.03]), and the need for invasive mechanical ventilation on the day of admission (OR = 1.97, CI [1.14-3.40]). The type of virus was not associated with mortality. After matching, patients with virus-detected ARF had lower mortality (OR = 0.77, CI [0.60-0.98]) than patients with ARF from other causes. This result was mostly driven by influenza-like viruses, namely, respiratory syncytial virus, parainfluenza virus, and human metapneumovirus (OR = 0.54, CI [0.33-0.88]). In immunocompromised patients with virus-detected ARF, mortality is high, whatever the species, mainly influenced by clinical severity and poor general status. However, compared to non-viral ARF, in-hospital mortality was lower, especially for patients with detected viruses other than influenza.
Sections du résumé
BACKGROUND
BACKGROUND
Acute respiratory failure (ARF) is the leading cause of ICU admission. Viruses are increasingly recognized as a cause of pneumonia in immunocompromised patients, but epidemiologic data are scarce. We used the Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie's database (2003-2017, 72 intensive care units) to describe the spectrum of critically ill immunocompromised patients with virus-detected ARF and to report their outcomes. Then, patients with virus-detected ARF were matched based on clinical characteristics and severity (1:3 ratio) with patients with ARF from other origins.
RESULTS
RESULTS
Of the 4038 immunocompromised patients in the whole cohort, 370 (9.2%) had a diagnosis of virus-detected ARF and were included in the study. Influenza was the most common virus (59%), followed by respiratory syncytial virus (14%), with significant seasonal variation. An associated bacterial infection was identified in 79 patients (21%) and an invasive pulmonary aspergillosis in 23 patients (6%). The crude in-hospital mortality rate was 37.8%. Factors associated with mortality were: neutropenia (OR = 1.74, 95% confidence interval, CI [1.05-2.89]), poor performance status (OR = 1.84, CI [1.12-3.03]), and the need for invasive mechanical ventilation on the day of admission (OR = 1.97, CI [1.14-3.40]). The type of virus was not associated with mortality. After matching, patients with virus-detected ARF had lower mortality (OR = 0.77, CI [0.60-0.98]) than patients with ARF from other causes. This result was mostly driven by influenza-like viruses, namely, respiratory syncytial virus, parainfluenza virus, and human metapneumovirus (OR = 0.54, CI [0.33-0.88]).
CONCLUSIONS
CONCLUSIONS
In immunocompromised patients with virus-detected ARF, mortality is high, whatever the species, mainly influenced by clinical severity and poor general status. However, compared to non-viral ARF, in-hospital mortality was lower, especially for patients with detected viruses other than influenza.
Identifiants
pubmed: 37833435
doi: 10.1186/s13613-023-01196-9
pii: 10.1186/s13613-023-01196-9
pmc: PMC10575827
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101Informations de copyright
© 2023. La Société de Réanimation de Langue Francaise = The French Society of Intensive Care (SRLF).
Références
Prevalence of Immunosuppression Among US Adults, 2013 | Hematology | JAMA | JAMA Network. https://jamanetwork.com/journals/jama/fullarticle/2572798 . Accessed 16 Apr 2022.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708 .
doi: 10.3322/caac.21708
pubmed: 35020204
Azoulay E, Russell L, Van de Louw A, et al. Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Med. 2020;46(2):298–314. https://doi.org/10.1007/s00134-019-05906-5 .
doi: 10.1007/s00134-019-05906-5
pubmed: 32034433
pmcid: 7080052
Azoulay E, Mokart D, Pène F, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study. J Clin Oncol. 2013;31(22):2810–8. https://doi.org/10.1200/JCO.2012.47.2365 .
doi: 10.1200/JCO.2012.47.2365
pubmed: 23752112
Azoulay E, Mokart D, Kouatchet A, Demoule A, Lemiale V. Acute respiratory failure in immunocompromised adults. Lancet Respir Med. 2019;7(2):173–86. https://doi.org/10.1016/S2213-2600(18)30345-X .
doi: 10.1016/S2213-2600(18)30345-X
pubmed: 30529232
Bird GT, Farquhar-Smith P, Wigmore T, Potter M, Gruber PC. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. Br J Anaesth. 2012;108(3):452–9. https://doi.org/10.1093/bja/aer449 .
doi: 10.1093/bja/aer449
pubmed: 22298243
Groeger JS, White P, Nierman DM, et al. Outcome for cancer patients requiring mechanical ventilation. J Clin Oncol. 1999;17(3):991–991. https://doi.org/10.1200/JCO.1999.17.3.991 .
doi: 10.1200/JCO.1999.17.3.991
pubmed: 10071294
Azevedo LCP, Caruso P, Silva UVA, et al. Outcomes for patients with cancer admitted to the ICU requiring ventilatory support: results from a prospective multicenter study. Chest. 2014;146(2):257–66. https://doi.org/10.1378/chest.13-1870 .
doi: 10.1378/chest.13-1870
pubmed: 24480886
Mokart D, Lambert J, Schnell D, et al. Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. Leuk Lymphoma. 2013;54(8):1724–9. https://doi.org/10.3109/10428194.2012.753446 .
doi: 10.3109/10428194.2012.753446
pubmed: 23185988
Chaoui D, Legrand O, Roche N, et al. Incidence and prognostic value of respiratory events in acute leukemia. Leukemia. 2004;18(4):670–5. https://doi.org/10.1038/sj.leu.2403270 .
doi: 10.1038/sj.leu.2403270
pubmed: 14762443
Azoulay É, Schlemmer B. Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Med. 2006;32(6):808–22. https://doi.org/10.1007/s00134-006-0129-2 .
doi: 10.1007/s00134-006-0129-2
pubmed: 16715324
Moreau AS, Peyrony O, Lemiale V, Zafrani L, Azoulay E. Acute respiratory failure in patients with hematologic malignancies. Clin Chest Med. 2017;38(2):355–62. https://doi.org/10.1016/j.ccm.2017.02.001 .
doi: 10.1016/j.ccm.2017.02.001
pubmed: 28477644
for the Efraim investigators and the Nine-I study group, Azoulay E, Pickkers P, et al. Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Med. 2017;43(12):1808–19. https://doi.org/10.1007/s00134-017-4947-1 .
doi: 10.1007/s00134-017-4947-1
Azoulay E, Lemiale V, Mokart D, et al. Effect of high-flow nasal oxygen vs standard oxygen on 28-day mortality in immunocompromised patients with acute respiratory failure: The HIGH randomized clinical trial. JAMA. 2018;320(20):2099. https://doi.org/10.1001/jama.2018.14282 .
doi: 10.1001/jama.2018.14282
pubmed: 30357270
pmcid: 6583581
Lemiale V, Resche-Rigon M, Azoulay E. Early non-invasive ventilation for acute respiratory failure in immunocompromised patients (IVNIctus): study protocol for a multicenter randomized controlled trial. Trials. 2014;15:372. https://doi.org/10.1186/1745-6215-15-372 .
doi: 10.1186/1745-6215-15-372
pubmed: 25257210
pmcid: 4190291
Contejean A, Lemiale V, Resche-Rigon M, et al. Increased mortality in hematological malignancy patients with acute respiratory failure from undetermined etiology: a Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie (Grrr-OH) study. Ann Intensive Care. 2016;6:102. https://doi.org/10.1186/s13613-016-0202-0 .
doi: 10.1186/s13613-016-0202-0
pubmed: 27783381
pmcid: 5080277
Dandachi D, Rodriguez-Barradas MC. Viral pneumonia: etiologies and treatment. J Investig Med. 2018;66(6):957–65. https://doi.org/10.1136/jim-2018-000712 .
doi: 10.1136/jim-2018-000712
pubmed: 29680828
Wu X, Wang Q, Wang M, et al. Incidence of respiratory viral infections detected by PCR and real-time PCR in adult patients with community-acquired pneumonia: a meta-analysis. Respiration. 2015;89(4):343–52. https://doi.org/10.1159/000369561 .
doi: 10.1159/000369561
pubmed: 25791384
Burk M, El-Kersh K, Saad M, Wiemken T, Ramirez J, Cavallazzi R. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev. 2016;25(140):178–88. https://doi.org/10.1183/16000617.0076-2015 .
doi: 10.1183/16000617.0076-2015
pubmed: 27246595
pmcid: 9487248
Alimi Y, Lim WS, Lansbury L, Leonardi-Bee J, Nguyen-Van-Tam JS. Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe. J Clin Virol. 2017;95:26–35. https://doi.org/10.1016/j.jcv.2017.07.019 .
doi: 10.1016/j.jcv.2017.07.019
pubmed: 28837859
pmcid: 7185624
Legoff J, Zucman N, Lemiale V, et al. Clinical significance of upper airway virus detection in critically ill hematology patients. Am J Respir Crit Care Med. 2019;199(4):518–28. https://doi.org/10.1164/rccm.201804-0681OC .
doi: 10.1164/rccm.201804-0681OC
pubmed: 30230909
Azoulay E, Mokart D, Rabbat A, et al. Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: prospective multicenter data. Crit Care Med. 2008;36(1):100–7. https://doi.org/10.1097/01.CCM.0000295590.33145.C4 .
doi: 10.1097/01.CCM.0000295590.33145.C4
pubmed: 18090351
Azoulay É, Mokart D, Lambert J, et al. Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. Am J Respir Crit Care Med. 2010;182(8):1038–46. https://doi.org/10.1164/rccm.201001-0018OC .
doi: 10.1164/rccm.201001-0018OC
pubmed: 20581167
Canet E, Osman D, Lambert J, et al. Acute respiratory failure in kidney transplant recipients: a multicenter study. Crit Care. 2011;15(2):R91. https://doi.org/10.1186/cc10091 .
doi: 10.1186/cc10091
pubmed: 21385434
pmcid: 3219351
Lemiale V, Mokart D, Resche-Rigon M, et al. Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA. 2015;314(16):1711. https://doi.org/10.1001/jama.2015.12402 .
doi: 10.1001/jama.2015.12402
pubmed: 26444879
Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367–76. https://doi.org/10.1093/cid/ciz1008 .
doi: 10.1093/cid/ciz1008
pubmed: 31802125
Shorr AF, Fisher K, Micek ST, Kollef MH. The burden of viruses in pneumonia associated with acute respiratory failure. Chest. 2018;154(1):84–90. https://doi.org/10.1016/j.chest.2017.12.005 .
doi: 10.1016/j.chest.2017.12.005
pubmed: 29274318
Walter JM, Wunderink RG. Testing for respiratory viruses in adults with severe lower respiratory infection. Chest. 2018;154(5):1213–22. https://doi.org/10.1016/j.chest.2018.06.003 .
doi: 10.1016/j.chest.2018.06.003
pubmed: 29908153
Bosaeed M, Kumar D. Seasonal influenza vaccine in immunocompromised persons. Hum Vaccines Immunother. 2018;14(6):1311–22. https://doi.org/10.1080/21645515.2018.1445446 .
doi: 10.1080/21645515.2018.1445446
Beck CR, McKenzie BC, Hashim AB, Harris RC, Nguyen-Van-Tam JS, University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012;206(8):1250–9. https://doi.org/10.1093/infdis/jis487 .
doi: 10.1093/infdis/jis487
pubmed: 22904335
Karbasi-Afshar R, Izadi M, Fazel M, Khedmat H. Response of transplant recipients to influenza vaccination based on type of immunosuppression: a meta-analysis. Saudi J Kidney Dis Transplant Off Publ Saudi Cent Organ Transpl Saudi Arab. 2015;26(5):877–83. https://doi.org/10.4103/1319-2442.164556 .
doi: 10.4103/1319-2442.164556
Liao Z, Tang H, Xu X, Liang Y, Xiong Y, Ni J. Immunogenicity and safety of influenza vaccination in systemic lupus erythematosus patients compared with healthy controls: a meta-analysis. PLoS ONE. 2016;11(2): e0147856. https://doi.org/10.1371/journal.pone.0147856 .
doi: 10.1371/journal.pone.0147856
pubmed: 26845680
pmcid: 4742052
Di Pasquale MF, Sotgiu G, Gramegna A, et al. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019;68(9):1482–93. https://doi.org/10.1093/cid/ciy723 .
doi: 10.1093/cid/ciy723
Rabello LSCF, Silva JRL, Azevedo LCP, et al. Clinical outcomes and microbiological characteristics of severe pneumonia in cancer patients: a prospective cohort study. PLoS ONE. 2015;10(3): e0120544. https://doi.org/10.1371/journal.pone.0120544 .
doi: 10.1371/journal.pone.0120544
pubmed: 25803690
pmcid: 4372450
COVID‐19 associated pulmonary aspergillosis - PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267243/ . Accessed 15 May 2022.
Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782–92. https://doi.org/10.1016/S2213-2600(18)30274-1 .
doi: 10.1016/S2213-2600(18)30274-1
pubmed: 30076119
Lortholary O, Gangneux JP, Sitbon K, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2011;17(12):1882–9. https://doi.org/10.1111/j.1469-0691.2011.03548.x .
doi: 10.1111/j.1469-0691.2011.03548.x
Pardo E, Lemiale V, Mokart D, et al. Invasive pulmonary aspergillosis in critically ill patients with hematological malignancies. Intensive Care Med. 2019;45(12):1732–41. https://doi.org/10.1007/s00134-019-05789-6 .
doi: 10.1007/s00134-019-05789-6
pubmed: 31599334
Garcia JB, Lei X, Wierda W, et al. Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc. 2013;10(5):432–40. https://doi.org/10.1513/AnnalsATS.201304-097OC .
doi: 10.1513/AnnalsATS.201304-097OC
pubmed: 23987587
pmcid: 3960911
Mokart D, Darmon M, Schellongowski P, et al. Acute respiratory failure in immunocompromised patients: outcome and clinical features according to neutropenia status. Ann Intensive Care. 2020;10(1):146. https://doi.org/10.1186/s13613-020-00764-7 .
doi: 10.1186/s13613-020-00764-7
pubmed: 33090310
pmcid: 7581668
Khawaja F, Chemaly RF. Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies. Haematologica. 2019;104(7):1322–31. https://doi.org/10.3324/haematol.2018.215152 .
doi: 10.3324/haematol.2018.215152
pubmed: 31221784
pmcid: 6601091
Shah DP, Shah PK, Azzi JM, El Chaer F, Chemaly RF. Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review. Cancer Lett. 2016;379(1):100–6. https://doi.org/10.1016/j.canlet.2016.05.035 .
doi: 10.1016/j.canlet.2016.05.035
pubmed: 27260872
pmcid: 4935561
Shah DP, Shah PK, Azzi JM, Chemaly RF. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review. Cancer Lett. 2016;370(2):358–64. https://doi.org/10.1016/j.canlet.2015.11.014 .
doi: 10.1016/j.canlet.2015.11.014
pubmed: 26582658